| Entry |
|
|---|
| Name |
Liraglutide (USAN/INN);
Liraglutide (genetical recombination) (JAN);
Victoza (TN) |
|---|
| Product |
|
|---|
| Formula |
C172H265N43O51
|
|---|
| Exact mass |
3748.9465
|
|---|
| Mol weight |
3751.202
|
|---|
| Sequence |
His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly
(-Glu combined: 20) |
|---|
| Type |
Peptide |
|---|
| Class |
|
|---|
| Remark |
| Therapeutic category: | 2499 |
| Product (mixture): | D11567<JP> |
|
|---|
| Efficacy |
Antidiabetic, Glucagon-like peptide 1 (GLP-1) receptor agonist |
|---|
| Disease |
Type 2 diabetes mellitus [DS: H00409] |
|---|
| Comment |
Human glucagon-like peptide 1 (GLP-1) [CPD: C16048] analog
Adjunctive thrapy to improve glycemic control, with diet and exercise in patients with type II diabetes
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Interaction |
|
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A10 DRUGS USED IN DIABETES
A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10BJ Glucagon-like peptide-1 receptor (GLP-1) analogues
A10BJ02 Liraglutide
D06404 Liraglutide (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Anti-Obesity Agents
Liraglutide
D06404 Liraglutide (USAN/INN)
Blood Glucose Regulators
Antidiabetic Agents
GLP-1 Receptor Agonist
Liraglutide
D06404 Liraglutide (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
24 Hormones
249 Miscellaneous
2499 Others
D06404 Liraglutide (USAN/INN); Liraglutide (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Secretin receptor family
Glucagon
GLP1R
D06404 Liraglutide (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D06404
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D06404
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D06404
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D06404
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
